Bridge Bio’s First-In-Class UC Contender Progresses After Positive Data
Early Line Oral Therapy?
Executive Summary
Positive interim results from first cohort in Phase IIa study with Bridge Therapeutics' first-in-class Pellino-1 inhibitor for ulcerative colitis set stage for higher doses with a possible change in clinical protocols.